The BH3-only protein Bad confers breast cancer taxane sensitivity through a nonapoptotic mechanism
A C Craik1, R A Veldhoen, M Czernick
1Department of Biochemistry, School of Molecular and Systems Medicine, University of Alberta, Edmonton, Alberta, Canada.
Abstract:
Antimitotic agents such as taxanes (paclitaxel and docetaxel) have greatly advanced the treatment of breast cancer, although variable patient response and drug toxicity are major limitations. Lack of validated predictive markers for taxane responsiveness precludes a priori identification of patients who are most likely to respond to treatment; thus, a subset of patients endure toxic side effects with marginal benefit. Mechanistic insights into taxane therapeutic activity may lead to rational therapeutic improvements. In this paper we report that the proapoptotic BH3-only protein Bad has a major role in taxane-induced cell death in vitro, and clinically is a prognostic indicator for overall survival of breast cancer patients after adjuvant taxane chemotherapy. Unexpectedly, Bad did not induce the mitochondrial apoptotic machinery in response to taxane treatment. Instead, Bad indirectly facilitated cell death by stimulating cellular proliferation. As dividing cells are the targets of taxane therapy, Bad-stimulated proliferation may be a marker of taxane sensitivity. Our studies indicate that quantification of Bad protein levels may have value as a diagnostic tool. They also suggest that cells expressing Bad are more sensitive to taxanes because of their altered cell cycle dynamics and reveal a clinically relevant proliferative role of Bad in breast cancer.
Insights
The proapoptotic protein Bad plays a key role in breast cancer treatment response to taxanes. Higher Bad levels indicate better survival, suggesting its potential as a predictive marker for taxane chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Taxanes (paclitaxel, docetaxel) are vital breast cancer treatments but have variable patient response and toxicity.
- Lack of predictive markers limits identifying patients who benefit most from taxanes, leading to unnecessary side effects.
Purpose of the Study:
- To investigate the role of the BH3-only protein Bad in taxane-induced cell death in breast cancer.
- To determine if Bad can serve as a predictive marker for taxane responsiveness and patient survival.
Main Methods:
- In vitro studies examining Bad's function in response to taxane treatment.
- Clinical analysis of Bad protein levels as a prognostic indicator in breast cancer patients receiving adjuvant taxane chemotherapy.
Main Results:
- The proapoptotic protein Bad is crucial for taxane-induced cell death in vitro.
- Bad levels are a significant prognostic indicator for overall survival in breast cancer patients treated with taxanes.
- Unexpectedly, Bad promoted cell proliferation, which may enhance sensitivity to taxanes as dividing cells are targeted.
Conclusions:
- Quantification of Bad protein levels could serve as a diagnostic tool for taxane sensitivity.
- Breast cancer cells expressing Bad exhibit increased sensitivity to taxanes due to altered cell cycle dynamics.
- Bad has a clinically relevant proliferative role in breast cancer, influencing taxane therapy outcomes.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:15Drugs that Stabilize Microtubules
02:23Abnormal Proliferation
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...